Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-21 06:21:17 Source:opinionsViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous:Mystery artist who erected signs comparing pothole
Next:Iran helicopter crash that killed President Raisi could reverberate across the Middle East
You may also like
- Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
- CONTRIBUTIONS STANDARD TERMS AND CONDITIONS
- US military ship heading to Gaza to build port
- LIZ JONES: Kate's strength has made me ashamed. And there's one self
- Sweden beats France, Britain relegated after losing to Norway at hockey worlds
- Queen Letizia and King Felipe of Spain visit Queen Sofia, 85, in hospital
- Thomas Kingston dies aged 45: How the royal family will form a tight circle of support around much
- How Princess Diana's audacious bid for freedom 30 years ago became a heart
- Why US Catholics are planning pilgrimages in communities across the nation